Development of dengue DNA vaccines

Vaccine

Volumn 29, Issue 42, 2011, Pages 7261-7266

  Danko, Janine R ^a   Beckett, Charmagne G ^a,b   Porter, Kevin R ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Clinical trials; Dengue; DNA vaccines; Non human primates; Shuffled DNA vaccines

Indexed keywords

DENGUE DNA VACCINE; DENGUE VACCINE; DNA VACCINE; PLASMID DNA; UNCLASSIFIED DRUG; VAXFECTIN;

ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CLINICAL EVALUATION; DENGUE; DRUG DESIGN; EXPERIMENTAL MODEL; HUMAN; NONHUMAN; PAIN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SWELLING; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; PLASMIDS; PRIMATES; VACCINES, DNA;

EID: 80052404085     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.019     Document Type: Article

References (35)

1. Mannino R.J., Gould-Fogerite S. Liposome mediated gene transfer. Biotechniques 1988, 6(July-August (7)):682-690.
2. Nicolau C., Le Pape A., Soriano P., Fargette F., Juhel M.F. In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. Proc Natl Acad Sci USA 1983 Feb, 80(February (4)):1068-1072.
3. Wolff J.A., Malone R.W., Williams P., Chong W., Acsadi G., Jani A., et al. Direct gene transfer into mouse muscle in vivo. Science 1990, 247(March (4949 Pt 1)):1465-1468.
4. Robinson H.L., Hunt L.A., Webster R.G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993, 11(9):957-960.
5. Tang D.C., De Vit M., Johnston S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356(6365):152-154.
6. Ulmer J.B., Donnelly J.J., Parker S.E., Rhodes G.H., Felgner P.L., Dwarki V.J., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993, 259(5102):1745-1749.
7. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time. Nat Rev Genet 2008, 9(October (10)):776-788.
8. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000, 18:927-974.
9. Lorenz I.C., Allison S.L., Heinz F.X., Helenius A. Folding and dimerization of tick-borne encephalitis virus envelope proteins prM and E in the endoplasmic reticulum. J Virol 2002, 76(June (11)):5480-5491.
10. Mukhopadhyay S., Kuhn R.J., Rossmann M.G. A structural perspective of the flavivirus life cycle. Nat Rev 2005, 3:13-22.
11. Men R.H., Bray M., Lai C.J. Carboxy-terminally truncated dengue virus envelope glycoproteins expressed on the cell surface and secreted extracellularly exhibit increased immunogenicity in mice. J Virol 1991, 65(3):1400-1407. ISSN:0022-538x.
12. Raviprakash K., Kochel T.J., Ewing D., Simmons M., Phillips I., Hayes C.G., et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000, 18(22):2426-2434.
13. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 2006, 24(January (3)):335-344.
14. Raviprakash K., Apt D., Brinkman A., Skinner C., Yang S., Dawes G., et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in Rhesus macaques. Virology 2006, 353(September (1)):166-173.
15. Lu Y., Raviprakash K., Leao I.C., Chikhlikar P.R., Ewing D., Anwar A., et al. Dengue 2 PreM-E/LAMP chimera targeted to the MHC class II compartment elicits long-lasting neutralizing antibodies. Vaccine 2003, 21(May (17-18)):2178-2189.
16. Raviprakash K., Porter K.R., Kochel T.J., Ewing D., Simmons M., Phillips I., et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000, 81(July (Pt 7)):1659-1667.
17. Kochel T.J., Raviprakash K., Hayes C.G., Watts D.M., Russell K.L., Gozalo A.S., et al. A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18(July (27)):3166-3173.
18. Raviprakash K., Ewing D., Simmons M., Porter K.R., Jones T.R., Hayes C.G., et al. Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 2003, 315(October (2)):345-352.
19. MacGregor R.R., Boyer J.D., Ugen K.E., Lacy K.E., Gluckman S.J., Bagarazzi M.L., et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998, 178(July (1)):92-100.
20. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006, 194(December (12)):1650-1660.
21. Martin J.E., Sullivan N.J., Enama M.E., Gordon I.J., Roederer M., Koup R.A., et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 2006, 13(November (11)):1267-1277.
22. Martin J.E., Pierson T.C., Hubka S., Rucker S., Gordon I.J., Enama M.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007, 196(December (12)):1732-1740.
23. Beckett C.G., Tjaden J., Burgess T., Danko J.R., Tamminga C., Simmons M., et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011, 29(January (5)):960-968.
24. Martin T., Parker S.E., Hedstrom R., Le T., Hoffman S.L., Norman J. et al. Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. Hum Gene Ther 1999, 10(March (5)):759-768.
25. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation 2004, Gene Ther, England, pp. 711-21.
26. Porter K.R., Kochel T.J., Wu S.J., Raviprakash K., Phillips I., Hayes C.G. Protective efficacy of a dengue 2 DNA vaccine in mice and the effect of CpG immuno-stimulatory motifs on antibody responses. Arch Virol 1998, 143(5):997-1003.
27. Gramzinski R.A., Maris D.C., Doolan D., Charoenvit Y., Obaldia N., Rossan R., et al. Malaria DNA vaccines in Aotus monkeys. Vaccine 1997, 15(8):913-915.
28. Le T.P., Coonan K.M., Hedstrom R.C., Charoenvit Y., Sedegah M., Epstein J.E., et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine 2000, 18(18):1893-1901.
29. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282(5388):476-480.
30. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10(April (4)):499-511.
31. Ledgerwood J.E., Pierson T.C., Hubka S.A., Desai N., Rucker S., Gordon I.J., et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011, 10(May (203)):1396-1404.
32. Smith L.R., Wloch M.K., Ye M., Reyes L.R., Boutsaboualoy S., Dunne C.E., et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010, 28(March (13)):2565-2572.
33. Barbon C.M., Baker L., Lajoie C., Ramstedt U., Hedley M.L., Luby T.M. In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization. Vaccine 2010, 28(November (50)):7852-7864.
34. Simmons M., Burgess T., Lynch J., Putnak R. Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 2010, 280-288.
35. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80(October (19)):9577-9585.